// App-Quantinova.ai

1935 : Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults

Researchers

Presenter

  • Philip C. Amrein

Principal Investigators

  • Kristen E. Stevenson

  • Traci M. Blonquist

  • Andrew M. Brunner

  • Gabriela S. Hobbs

  • Hanno R. Hock

  • Steven L. McAfee

  • Jenna A. Moran

  • Meghan Bergeron

  • Julia E. Foster

  • Christina Bertoli

  • Kristin McGregor

  • Molly Macrae

  • Meghan Burke

  • Tanya T. Behnan

  • Tina T. Som

  • Aura Y. Ramos

  • Megan K. Vartanian

  • Jennifer Lombardi Story

  • Christine Connolly

  • Timothy A. Graubert

  • Donna S. Neuberg

  • Amir T. Fathi

Medical Centers

  • Leukemia Center/MGH Cancer Center, Massachusetts General Hospital, Belmont, MA

  • Hematology Oncology, University of Virginia, Charlottesville, VA

  • Department of Imaging, Dana-Farber Cancer Institute, Boston, MA

  • Data Science, Dana-Farber Cancer Institute, Boston, MA

  • Center for Cancer Research, Massachusetts General Hospital, Boston, MA

  • Transplant Center, Massachusetts General Hospital, Boston, MA

  • Biostatistics Center, Massachusetts General Hospital/Harvard Medical School, Boston, MA

  • Massachusetts General Hospital, Blood and Marrow Transplant Program, Boston, MA

  • Leukemia Center, Massachussets General Hospital, Charlestown, MA

  • Leukemia Center, Massachusetts General Hospital, Center for Leukemia, Cambridge, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • Ph chromosome

Drug/Treatment

  • dasatinib

  • Ixazomib

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved